Healthcare Industry News: Microbia
News Release - December 16, 2009
GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore TreatmentNext advance in the treatment of cold sores
Strengthens a key OTC franchise
PARSIPPANY, N.J. and ANN ARBOR, Mich., Dec. 16 (Healthcare Sales & Marketing Network) -- GlaxoSmithKline plc [GSK] (NYSE: GSK) and NanoBio Corporation today announced an exclusive licensing agreement in the United States and Canada for the over-the-counter (OTC) use of NB-001, a novel, patented compound representing the next advance in the treatment of cold sores. Developed by NanoBio, NB-001 provides significant antiMicrobial activity against the virus that causes cold sores, herpes labialis.
Cold sores are a prevalent condition affecting approximately 20% of the adult population in the US. GSK has established Abreva® as the leading cold sore treatment with a greater than 50% share, gaining two share points in the prior 12 months. Abreva is the only OTC medicine approved by the US Food & Drug Administration that is proven to shorten cold sore healing time.
NanoBio has completed two Phase 2 clinical trials of NB-001, demonstrating clear efficacy and a good safety profile in patients and plans to enter Phase 3 testing soon.
Under the terms of the agreement, NanoBio will receive an upfront payment of $14.5 million, and is eligible to receive additional milestone payments of up to $40 million plus single digit royalties on future sales.
"I am pleased to announce this partnership with GSK as it will enable the development and commercialization of NB-001 to its fullest potential," said James R. Baker, Jr., MD, NanoBio's CEO and founder. "GSK's demonstrated leadership in developing and marketing consumer healthcare products, including the leading product for the treatment of herpes labialis, makes them the ideal partner for NB-001. On a broader scale, this partnership further validates the promise of our proprietary platform technology, and its potential use in a wide range of dermatological and anti-infective applications."
Roger Scarlett-Smith, President, GSK Consumer Healthcare North America noted, "We are always looking for innovations that bring value to the consumer. This agreement with NanoBio strengthens our leadership position in the cold sore category. With Abreva, we have a very effective cold sore treatment in the category and look forward to building on that platform with this new technology from NanoBio."
NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan.
GlaxoSmithKline Consumer Healthcare is one of the world's largest over-the-counter consumer healthcare products companies. Its more than 30 well-known brands include the leading smoking cessation products, Nicorette® and NicoDerm®CQ®, and Commit®, as well as many medicine cabinet staples -- alli®, Aquafresh®, Sensodyne®, and TUMS® -- which are trademarks owned by and/or licensed to GlaxoSmithKline Group of Companies.
GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsTheravance Biopharma Highlights Positive Top-Line Results From Pivotal Phase 3 FULFIL Study of the Closed Triple Announced by GlaxoSmithKline and Innoviva
Avalon Ventures and COI Pharmaceuticals Announce First Milestones for Sitari Pharmaceuticals and Silarus Therapeutics and Formation of Eighth Company
Lannett Receives FDA Approval For Sumatriptan Nasal Spray USP, 5mg And 20mg